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Introduction: Alpha-1-antitrypsin deficiency (A1AD) is a hereditary disorder, caused by 
insufficiency or lack o f hepatic enzyme alpha-1-antitrypsin, which blocks neutrophil elastase. A1AD could 
affect any organs, but mostly the respiratory system is involved. A1AD pulmonary manifestations are 
panacinar emphysema and COPD. Usually emphysema appeal's at the age o f 30 -  40 years old, in smokers 
A1 AD subjects, but also can occurred at 50-60 years old in A1 AD patients how have never smoked.
Clinical Case: 41 years old man, current smoker (smoker index - 30 packs/year), was 
admitted for dyspnea at rest, cough with mucopurulent sputum, 38°C fever, loss o f  appetite and 
asthenia. At the same time he mentioned that he has experienced a progressive dyspnea during the 
last four years. Physical exam revealed: low body weight (BMI 18.5), tachycardia (HR-130 
beats/min), tachypnea (RR-26/min) andSa02-91% (F i0 2-21%). Signs o f  lung hyperinflationas well 
assigns o f  pulmonary consolidation were found. Laboratory data highlighted leukocytosis up to 
16x109/l and increased ESR 52 mm/hour. On ECG - signs o f  pulmonary cord were attested. The 
chest X ray revealed bilateral opacities in S9-S10, andradiographic signs o f  pulmonary 
hyperinflation. Pulmonary function tests shown obstructive abnormalities (FVC-38%, VEMS-20%, 
VEMS/FVC -56%) with hyperinflation (RV-188%) and a decreased gas transfer factor (DLCO- 
27%). Chest CT scan revealed diffuse panlobular emphysema and apical areas o f centrilobular 
emphysema, thickening o f the bronchial walls, and basal areas o f pulmonary consolidation in both 
lungs. The serum level o f  alpha-1-antitrypsin was 0.27 g/1 (normal range 0.9 to 2 g/1).
Results: In 2003, ERS/ATS has published the guidelines on the diagnosis and management o f the 
A1 AD. The groups o f  patients in whom A1 AD testing is recommended are young adults with persistent 
bronchial obstruction syndrome, emphysema, COPD, asthma and asymptomatic individuals with 
persistent bronchial obstruction or those with such risk factors as smoking or occupational exposure.
C onclusion: A1AD is an underdiagnosed disease in patients with chronic obstructive 
pulmonary disease. The gold standard for A1AD diagnosis is the genetic test (determining the 
pathogenic version o f  the gene encoding alpha-1-antitrypsin - SERPINA1), but for screening 
purpose, methods o f  quantitative assessment o f  serum levels o f  alpha-1-antitrypsin may be useful.
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Introduction: Sweating is a healthy natural physiological phenomenon, with an essential role 
in thermoregulation and detoxification processes o f  the body. But there exist such phenomena as 
sweating disorders wich include: hypohidrosis, anhydrosis and hyperhidrosis.
Purpose and objectives: The study o f  sweating disorders in patients with chronic migraine 
and chronic low back pain. (1) Evaluation o f  perspiration and sweating disorders in these patients. 
(2) Determination o f  hyperhidrosis action on quality o f  life. (3) Identification o f  anxiety and 
depression in chronic pain patients with hyperhidrosis. (4) Comparing sweating in higher humidity 
region for patients with chronic migraine, chronic low back pain and control group.
Materials and methods: The study was conducted on a total o f  40 patients aged between 20- 
65 years, o f  which 20 patients (women) with chronic migraine (group I) and 20 patients (10 men 
and 10 women) with chronic low back pain (group II) and 10 healthy subjects aged between 25-58
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